Intellectual Property — Updated March 3, 2026
Surnetics technology is protected by a portfolio of 5 granted US patents with continuation applications extending protection through 2041. Partners gain exclusive access to technology that cannot be commercially replicated.
5
Granted Patents
3
Pending Applications
44
Patent Citations
2041
Portfolio Extends To
Granted US Patents
Patents cover the core methods, products, and devices built on Surface Energy Gradient Coating technology. Click any patent number to view the full document.
Pending US Applications
Continuation applications extend and expand the scope of protection, preserving priority dates while broadening the claim landscape through 2041.
When 44 subsequent patents from major industry players cite this work, it is evidence of broad technological relevance — validation that this is foundational IP, not a niche filing. This citation record demonstrates the core science underpins a wide range of downstream applications and commercial interests.
Who Is Citing This Work
IVD & Diagnostics Manufacturers
Publicly traded medical device companies developing cartridge-based diagnostic systems
Academic & Research Institutions
University laboratories and national research centers advancing microfluidic science
Medical Device Companies
Instrument manufacturers and diagnostic platform developers across POC and lab settings
Full list of citing patents and assignees available for review under NDA.
44
Patent Citations
Technology Readiness
The Surface Gradient Coating technology is production-ready with established manufacturing processes, proven quality metrics, and over a decade of real-world validation with diagnostic companies.
Programmable, automated system for large-scale manufacturing coating process designed and installed.
Can be adapted to a variety of precision coating systems.
Can easily be scaled for larger applications.
Manufacturing costs and manufacturing quality established for the coating process.
PFAS-free hydrophobic coatings developed.
Coatings with FDA-approved chemistry developed.
Products have been produced for and tested with diagnostic companies since 2014.
Demonstrated that gradient coatings control flow rates to targeted flow rates with <10% variation across manufactured lots.
Coatings have been used with blood, plasma, wash solutions, and other reagent liquids.
Additional Assets
Beyond the patent portfolio, Surnetics offers access to valuable proprietary knowledge and trade secrets — available along with technical training for qualified partners.
Technical training available with IP transfer or licensing agreements.
Coating formulations for metal, glass, and plastic surfaces.
Coating processes and equipment specifications.
Predictive flow model and material test data for product designs.
Preferred materials and coating compositions with specific liquids.
Ideal Partners & Acquirers
The microfluidics diagnostics market is $12B+ and growing at 20% annually. The companies below are the primary commercial universe for this technology — each actively developing or acquiring microfluidic and point-of-care diagnostic IP.
Abbott Laboratories
i-STAT · BinaxNOW POC
Thermo Fisher Scientific
Molecular Diagnostics
Becton Dickinson
Diagnostics Systems
Danaher / Cepheid
Rapid Molecular Testing
Bio-Rad Laboratories
Clinical Diagnostics
Hologic
Women’s Health IVD
Qiagen
Sample Prep & Assays
Illumina
Genomics Platforms
Deal Structures Available
We are open to multiple deal structures depending on the partner's needs and strategic objectives.
Outright Portfolio Sale
One-time payment for full ownership transfer of all 5 granted patents and 3 pending applications. Simplest structure for a strategic acquirer.
Exclusive License
Upfront payment plus royalties. You gain exclusive rights to commercialize across agreed fields of use — we retain nominal ownership.
Field-of-Use License
Exclusive rights in one sector (e.g., diagnostics) while we license separately to non-competing markets (e.g., aerospace). Maximizes value for both parties.
Co-Development Agreement
Joint development partnership to extend the technology into your specific product platform — with milestone payments and licensing terms.
Valuation & Pricing
Pricing Available to Qualified Parties
Portfolio valuation and pricing details are available to qualified parties following NDA execution. To receive our confidential information memorandum, please contact us or email us directly at info@surnetics.com.
Request One-Page SummaryWe are actively pursuing licensing partnerships, co-development agreements, and strategic partnerships across our six target markets. Patent protection active through 2041 provides a long runway for partners to build on this technology.